{"id":"bupropion-sustained-release","safety":{"commonSideEffects":[{"rate":"null","effect":"Insomnia"},{"rate":"null","effect":"Dry mouth"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bupropion works by inhibiting the reuptake of norepinephrine and dopamine in the brain, increasing their levels and activity.","oneSentence":"Norepinephrine-dopamine reuptake inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:23:21.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"}]},"trialDetails":[{"nctId":"NCT06958692","phase":"PHASE3","title":"A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-04-11","conditions":"Major Depressive Disorder (MDD)","enrollment":388},{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":"Major Depressive Disorder (MDD)","enrollment":120},{"nctId":"NCT03047005","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-28","conditions":"Binge-Eating Disorder, Obesity","enrollment":68},{"nctId":"NCT00572234","phase":"NA","title":"Bupropion in the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2007-08-31","conditions":"Methamphetamine Use Disorder","enrollment":40},{"nctId":"NCT03045341","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-02-27","conditions":"Binge-eating Disorder, Obesity","enrollment":136},{"nctId":"NCT03471767","phase":"PHASE2","title":"AXS-05 Phase II Trial on Smoking Behavior","status":"COMPLETED","sponsor":"James Davis","startDate":"2018-03-25","conditions":"Smoking Cessation, Smoking, Cigarette, Nicotine Dependence","enrollment":58},{"nctId":"NCT00296517","phase":"PHASE3","title":"Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-19","conditions":"Depressive Disorder","enrollment":325},{"nctId":"NCT01592695","phase":"PHASE2","title":"Tailored Tobacco Quitline for Rural Veterans","status":"COMPLETED","sponsor":"Iowa City Veterans Affairs Medical Center","startDate":"2012-06","conditions":"Cigarette Smoking","enrollment":63},{"nctId":"NCT02593396","phase":"PHASE2","title":"Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2015-12","conditions":"Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder, Erectile Dysfunctions","enrollment":80},{"nctId":"NCT02994082","phase":"NA","title":"Treating Smokeless Tobacco Use in Rural Veterans","status":"UNKNOWN","sponsor":"Mark Vander Weg","startDate":"2016-12","conditions":"Smokeless Tobacco, Nicotine Dependence","enrollment":123},{"nctId":"NCT03126682","phase":"PHASE4","title":"Effect of Bupropion on Seizure Threshold in Depressed Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-25","conditions":"MDD","enrollment":10},{"nctId":"NCT03920319","phase":"PHASE1","title":"Bupropion and Cigarette-Related Cues in Smokers","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2004-01-01","conditions":"Smoking, Smoking, Tobacco","enrollment":34},{"nctId":"NCT01138007","phase":"PHASE3","title":"A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-17","conditions":"Depressive Disorder, Major","enrollment":572},{"nctId":"NCT02238977","phase":"PHASE4","title":"Bupropion for Depression in ESRD Patients on Hemodialysis","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2016-03-31","conditions":"Major Depression, End Stage Renal Disease","enrollment":1},{"nctId":"NCT01714323","phase":"NA","title":"Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-12","conditions":"Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder","enrollment":1359},{"nctId":"NCT02078180","phase":"PHASE4","title":"Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2014-04","conditions":"Depression","enrollment":34},{"nctId":"NCT02162862","phase":"PHASE4","title":"Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Eva Szigethy","startDate":"2013-07","conditions":"Sleep Disturbance, Fatigue, Inflammatory Bowel Disease","enrollment":99},{"nctId":"NCT00625859","phase":"PHASE1","title":"A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-16","conditions":"Diabetes Mellitus, Type 2","enrollment":27},{"nctId":"NCT00864981","phase":"PHASE1","title":"A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-09","conditions":"Depression","enrollment":32},{"nctId":"NCT00063323","phase":"PHASE3","title":"Maintenance Treatment for Abstinent Smokers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2000-08","conditions":"Tobacco Use Disorder","enrollment":589},{"nctId":"NCT00593099","phase":"PHASE1, PHASE2","title":"A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2004-04","conditions":"Bipolar Disorder","enrollment":5},{"nctId":"NCT00307203","phase":"PHASE4","title":"Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1998-08","conditions":"Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders","enrollment":51},{"nctId":"NCT02173886","phase":"PHASE4","title":"A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery","status":"COMPLETED","sponsor":"North Dakota State University","startDate":"2014-06","conditions":"Roux en Y Gastric Bypass","enrollment":20},{"nctId":"NCT01286402","phase":"PHASE2","title":"Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-04","conditions":"Smoking Cessation","enrollment":11},{"nctId":"NCT01764386","phase":"PHASE3","title":"Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2013-02","conditions":"Obesity, Overweight","enrollment":242},{"nctId":"NCT00711477","phase":"PHASE2","title":"A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2008-09","conditions":"Obesity","enrollment":46},{"nctId":"NCT00456521","phase":"PHASE3","title":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-03","conditions":"Obesity, Overweight","enrollment":793},{"nctId":"NCT00567255","phase":"PHASE3","title":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-12","conditions":"Obesity, Overweight","enrollment":1496},{"nctId":"NCT00532779","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-10","conditions":"Obesity, Overweight","enrollment":1742},{"nctId":"NCT00474630","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-05","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":505},{"nctId":"NCT00625131","phase":"EARLY_PHASE1","title":"Nicotine Patch Pretreatment for Smoking Cessation in PTSD","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2008-05","conditions":"Stress Disorders, Posttraumatic, Tobacco Use Disorder","enrollment":87},{"nctId":"NCT00308763","phase":"NA","title":"Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2004-01","conditions":"Tobacco Use Disorder","enrollment":594},{"nctId":"NCT00833443","phase":"PHASE2","title":"Study of Medical Treatment for Methamphetamine Addiction","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-01","conditions":"Methamphetamine, Amphetamine Dependence, Pharmacogenetics","enrollment":84},{"nctId":"NCT01875172","phase":"PHASE2","title":"Bupropion for Smoking Cessation in Pregnancy","status":"COMPLETED","sponsor":"Watching Over Mothers & Babies Foundation","startDate":"2001-10","conditions":"Smoking Cessation, Pregnancy","enrollment":135},{"nctId":"NCT00709371","phase":"PHASE2","title":"Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2008-07","conditions":"Obesity","enrollment":729},{"nctId":"NCT00563563","phase":"PHASE2","title":"A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-10","conditions":"Nicotine Dependence, Overweight, Obesity","enrollment":30},{"nctId":"NCT00624858","phase":"PHASE2","title":"A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2008-01","conditions":"Depression","enrollment":25},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00865111","phase":"PHASE1","title":"A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":26},{"nctId":"NCT00419731","phase":"PHASE2, PHASE3","title":"Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation","status":"UNKNOWN","sponsor":"University of Minnesota","startDate":"2006-11","conditions":"Tobacco Use Disorder","enrollment":120},{"nctId":"NCT00484692","phase":"PHASE4","title":"Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2005-07","conditions":"Nicotine Dependence, Substance Abuse, Substance Dependence","enrollment":779},{"nctId":"NCT00181818","phase":"PHASE4","title":"Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"1999-10","conditions":"Smoking, Myocardial Infarction, Unstable Angina","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":172,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyban","Zyban, Wellbutrin"],"phase":"phase_2","status":"active","brandName":"Bupropion Sustained Release","genericName":"Bupropion Sustained Release","companyName":"Iowa City Veterans Affairs Medical Center","companyId":"iowa-city-veterans-affairs-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norepinephrine-dopamine reuptake inhibitor Used for Major depressive disorder, Seasonal affective disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}